DSHB

上海文乐生物科技有限公司是DSHB公司中国一级代理商




Developmental Studies Hybridoma Bank
The DSHB was created in 1986 by the Institute of Child Health and Human Development (NIH) to bank and distribute hybridomas and the monoclonal antibodies (MAbs) they produce to the general scientific community in order to facilitate research. One intention was, and still is, to keep the price of the MAbs low so that researchers can test multiple MAbs without commitment of significant funds, then continue to utilize those of interest without worry of expense. A second intent was to relieve scientists of the time and expense of distributing hybridomas and MAbs they had developed. A third intent was to assure the scientific community that MAbs with limited demand would still remain available. We have strived over the past 23 years to remain true to our mission.
Since 1996 we have been completely self-sufficient, requiring no funds from NIH. The DSHB continues to respond rapidly to queries by customers concerning product quality and application. If there is a problem with a supernatant, we immediately retest it and, if necessary, immediately reclone the hybridoma cell line. In the past two years, we have recloned 200 lines, with an average increase in immunoglobulin productions of 71%. The Bank has been moved to new facilities for better quality control. It is one third of the way through a two year program to reclone and characterize the major 400 lines for optimum antibody production and higher supernatant titers. The DSHB now banks close to 1100 hybridomas and has been growing at a rate of 10 to 20% a year. Recently we obtained a collection of hybridomas against proteins involved in muscular dystrophies, and a collection against the major cytoskeletal elements of the model organism Dictyostilium discoideum. We also received the first 200 hybridomas that will eventually expand to thousands of hybridomas against proteins involved in cancer from an NCI initiative.
We have recently been promised several additional collections. In 2008, we initiated the DSHB-Microbe, which will bank and distribute hybridomas against viral, bacterial, fungal and parasitic antigens. We have also begun development of antibody chips which will contain between 50 and 500 antibodies against related targets. They should be available in late 2009, at cost. Finally, we have begun to develop the DSHB Institute for Monoclonal Antibody Research which will focuson cancer diagnosis and cancer stem cells. In the last twelve months, we have filled over 9000 orders for more than 30,000 supernatant samples and/or hybridomas.
Our mission is to continue to grow and serve the needs of the scientific community, as we have done now for over 20 years. And our prices will remain low and our quality high.